Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis

Clinical and Experimental Immunology

Volumn 104, Issue 1, 1996, Pages 167-172

  Levy, Y ^a   Labaume, S ^b   Colombel, M ^a   Brouet, J C ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

apoptosis; IL 6; IL 6 receptor; multiple myeloma; retinoic acid

Indexed keywords

CYTOKINE RECEPTOR; GLYCOPROTEIN; INTERLEUKIN 6; ONCOPROTEIN; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL LINE; DOWN REGULATION; HUMAN; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0029901305     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-637.x     Document Type: Article

References (27)

1. Sporn MB, Roberts AB. Role of retinoids in differentiation and carcinogenesis. Cancer Res 1983; 43:3034-9.
2. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem Biophys Acta 1980; 605:33-39.
3. De Luca LM. Retinoids and their receptors in differentiation embryogenesis, and neoplasia. FASEB J 1991; 5:2924-33.
4. Blomhoff HK, Smeland EB, Erikstein B, Rasmussen AM, Skrede B, Skjonsberg C, Blomhoff R. Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cells. J Biol Chem 1992; 267:2398-9.
5. Sidell N, Ramsdell F. Retinoic acid upregulates interleukin-2 receptors on activated human thymocytes. Cell Immunol 1988; 115:299-309.
6. Jetten AM. Fffects of retinoic acid on the binding and mitogenic activity of epidermal growth factor. J Cell Physiol 1982; 110:235-40.
7. Haskell BF, Stach RW, Werrbach-Perez K, Perez-Polo JR. Effect of retinoic acid on nerve growth factor receptors. Cell Tissue Res 1987; 247:67-73.
8. Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72:567-72.
9. Castaigne S, Chomienne C, Daniel T, Ballerini P, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990 76:1704-9.
10. Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 1991; 146:3809-14.
11. Ogata A, Nishimoto N, Shima Y, Yoshizaki K, Kishimoto T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994; 84:3040-6.
12. Kawano M, Hirano T, Matsuda T et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332:83-85.
13. Klein B, Zhang XG, Jourdan M et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73:517-26.
14. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood 1989; 73:1915-24.
15. Levy Y, Tsapis A, Brouet JC. Interleukin-6 antisense oligonucleotides inhibit the growth of human myeloma cell lines. J Clin Invest 1991; 88:696-9.
16. Nilsson K, Bennich A, Johansson SGO, Potent J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 1970; 7:477-80.
17. Moore GE, Marbell JW, Woods LK, Morgan KT, Semple TV. RPMI 8226, a human myeloma cell line: an update. Proc Am Assoc Cancer Res 1982; 33:126-9.
18. Gold R, Schmied M, Rothe G, Zischler H, Breitschopf H, Wekerle H, Lassmann H. Detection of DNA fragmentation in apoptosis: application of in situ nick translation to cell culture systems and tissue sections. J Histochem Cytochem 1993; 41:1023-30.
19. Levy Y, Labaume S, Gendron MC, Brouet JC. Modulation of spontaneous B-cell differentiation in macroglobulinemia by retinoic acid. Blood 1994; 83:2206-10.
20. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto T. Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 1990; 63:1149-57.
21. Murakami M, Hibi M, Nakagawa N et al. IL-6 induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993; 260:1808-10.
22. Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: a paradigm for cytokines. Science (Wash DC) 1992; 258:593-7.
23. Mazars GR, Portier M, Zhang XG, Jourdan M, Bataille R, Theillet C, Klein B. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7:1015-8.
24. Lotem J, Cragoe EJ Jr, Sachs L. Rescue from progammed cell death in leukemic and normal myeloid cells. Blood 1991; 78:953-60.
25. Yonish-Rouuch E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-7.
26. Muindi JRF, Young CW, Warrell RP Jr. Clinical pharmacology of all-trans retinoic acid. Leukemia 1994; 8:1807-12.
27. Vesole D, Kornbluth J, Jagannath S et al. Biological response modifiers (BRM) in refractory multiple myeloma (MM). Blood 1982; 263a, 1993 (Abst. Suppl.).